Myelomonocytic Leukemia
📧 Sign up to get email alerts when something new happens for Myelomonocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Inqovi Maintenance Therapy in Myeloid Neoplasms [Phase 1]
Phase 1 trial update on Inqovi as maintenance therapy for myeloid neoplasms, including myelodysplastic syndromes and chronic myelomonocytic …
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML [Phase 1, Phase 2]
Clinical trial update for S227928 as a single agent and in combination with Venetoclax in relapsed/refractory AML, MDS/AML, and CMML shows t…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia [EARLY_Phase 1]
This early-phase trial update describes a study evaluating momelotinib in combination with a hypomethylating agent for Chronic Myelomonocyti…
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating NMS-03592088 in relapsed or refractory acute myeloid leukemia and chronic myelomonocytic leukemia has …
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. [Phase 1]
This clinical trial update describes a Phase 1 study of CD4CAR CAR-T therapy as a second-line treatment for chronic myelomonocytic leukemia …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS [Phase 1]
Phase 1 clinical trial evaluating a combination of epigenetic therapy and sensitising therapy in acute myeloid leukemia, myelodysplastic syn…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation [Phase 2]
This Phase 2 clinical trial protocol investigates a post-transplant cyclophosphamide–based graft-versus-host disease prophylaxis approach in…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias [Phase 1]
Clinical trial update for CBX-250 in relapsed or refractory myeloid leukemias (Phase 1) that is currently recruiting at Crossbow Therapeutic…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia [Phase 1, Phase 2]
Clinical trial update on Axatilimab with or without Azacitidine for advanced myeloproliferative neoplasms, including MDS/MPN overlap and hig…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia [Phase 2]
This clinical trial update describes a Phase 2 study of Ropeginterferon alfa-2b for treating myelodysplastic/myeloproliferative neoplasm ove…
-
CLINICAL_TRIALS withdrawal · 2026-03-12Clinical Trial Update: Calprotectin, a Biomarker of COVID-19 Severity (CALPRO) [NA]
A clinical trial evaluating calprotectin (CALPRO) as a biomarker for COVID-19 severity (NCT04953312) has been withdrawn; the study also invo…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation [Phase 2]
Phase 2 trial update on enasidenib with azacitidine for recurrent or refractory acute myeloid leukemia with IDH2 mutation, currently recruit…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) [Phase 2]
Phase 2 clinical trial evaluating azacitidine in combination with venetoclax for higher-risk chronic myelomonocytic leukemia is active/not r…
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia [Phase 1]
A Phase 1 trial is evaluating CLAG-M or FLAG-Ida chemotherapy with reduced-intensity conditioning donor stem cell transplant for relapsed or…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant [Phase 1]
A Phase 1 clinical trial update assessing olutasidenib for IDH1-mutated acute myeloid leukemia, myelodysplastic syndrome, or chronic myelomo…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia [Phase 2]
This Phase 2 trial compares pacritinib to hydroxyurea in advanced proliferative chronic myelomonocytic leukemia and is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. [Phase 2]
Phase 2 study evaluating olutasidenib in IDH1-mutated clonal cytopenia of undetermined significance and lower-risk myelodysplastic syndromes…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia [Phase 1]
Phase 1 trial evaluating the safety of a multi-agent regimen (CDX-1401, Poly ICLC, Decitabine, and Nivolumab) in patients with myelodysplast…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms [Phase 1]
This clinical trial update notes a Phase 1 study of Onvansertib for recurrent or refractory chronic myelomonocytic leukemia and myelodysplas…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome [Phase 2]
Phase 2 trial evaluating liposome-encapsulated daunorubicin-cytarabine (CPX-351) in combination with gemtuzumab ozogamicin for relapsed or r…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS [Phase 2, Phase 3]
A phase 2/3 clinical trial is investigating venetoclax in combination with a fractionated busulfan conditioning regimen for high-risk acute …
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluates venetoclax combined with ASTX727 (oral decitabine/cedazuridine) in treatment-naive high-risk myelodyspl…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders [Phase 2]
Phase 2 clinical trial update evaluating a geriatric assessment to guide treatment planning for older adults with myelodysplastic syndromes,…
-
CLINICAL_TRIALS withdrawal · 2026-02-12Clinical Trial Update: Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome [Phase 1, Phase 2]
A phase 1/2 clinical trial testing venetoclax in combination with azacitidine for high-risk recurrent or refractory myelodysplastic syndrome…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: LILRB4 STAR-T Cell Therapy for Monocytic Leukemia [NA]
A clinical trial evaluating LILRB4 STAR-T Cell Therapy for monocytic leukemia has completed its study for Acute Myeloid Leukemia and Chronic…